

Supporting Information

Grafting synthetic transmembrane units to the engineered low-toxicity α -hemolysin to restore its hemolytic activity

Mihoko Ui,^{*a} Kousuke Harima,^a Toshiaki Takei,^b Kouhei Tsumoto,^{b,c,d} Kazuhito V. Tabata,^e Hiroyuki Noji,^e Sumire Endo,^a Kimio Akiyama,^a Takahiro Muraoka,^a and Kazushi Kinbara^{*a}

^a *Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, 2-1-1, Katahira, Aoba-ku, Sendai 980-8577, Japan.*

^b *Department of Medical Genome Sciences, Graduate School of Engineering, The University of Tokyo, 5-1-5 Kashiwanoha, Kashiwa 277-8562, Japan.*

^c *Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.*

^d *Department of Bioengineering and Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.*

^e *Department of Applied Chemistry, School of Engineering, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8656, Japan.*

E-mail: kinbara@tagen.tohoku.ac.jp

Contents

- 1. Size-exclusion chromatography of the stem-truncated mutants (STM1-6)**
- 2. Size-exclusion chromatography of STM6 with multiangle light scattering (SEC-MALS) analysis**
- 3. Western blot analysis of STM5 and STM6 binding to SRBCs**
- 4. Hemolytic activity of 14-meric and 7-meric forms of STM5**
- 5. Transmission electron microscopy of STM5 with 6.25 mM sodium deoxycholate**
- 6. Electron paramagnetic resonance (EPR) spectroscopy of spin-labeled STM5**
- 7. Electron paramagnetic resonance (EPR) spectroscopy of spin-labeled STM2 in a monomeric form**
- 8. Western blot analysis of STM5, STM5-PhM, STM5-PyM, and STM5-FIM**
- 9. Hemolytic activity of PyM-modified stem-truncated Hla mutant K46C**
- 10. The conductance of membranes containing STM5, STM5-PyM, and STM5-FIM**
- 11. Absorption and fluorescence spectroscopy of STM5-PyM**
- 12. Hemolytic activity of chemically-modified STM6**
- 13. The far-UV CD spectra of STM5 and STM5-PyM**

1. Size-exclusion chromatography of the stem-truncated mutants (STM1-6)




Figure S1. Size-exclusion chromatograms of (a) STM1, (b) STM2, (c) STM3, (d) STM4, (e) STM5, and (f) STM6. The proteins in Tris-HCl buffer (pH 8.0; 50 mM; containing 200 mM NaCl, 200 mM arginine hydrochloride, and 5 mM dithiothreitol) were loaded onto a HiLoad 26/60 Superdex 200-pg column pre-equilibrated with the same buffer. Each elution peak is identified as monomer, 7-mer, or 14-mer based on the elution volumes of molecular weight standards, respectively.

2. Size-exclusion chromatography of STM6 with multiangle light scattering (SEC-MALS) analysis




Figure S2. Size-exclusion chromatogram of STM6 (red) for (a) the 14-meric and (b) 7-meric forms in Tris-HCl buffer (pH 8.0; 50 mM; containing 200 mM NaCl and 200 mM arginine hydrochloride) detected by refractive index (RI) signals. The orange dots represent the molecular weight evaluated by MALS analysis.

3. Western blot analysis of STM5 and STM6 binding to SRBCs




Figure S3. Western blot analysis of STM5 and STM6 binding to sheep red blood cells (SRBCs). The stem-truncated mutants STM5 and STM6 (each 0.2 mg/mL) were incubated with SRBCs (50 mL, OD₇₀₀ = 0.5) in PBS buffer (pH 7.4; containing 200 mM arginine hydrochloride) for a definite period of time at 25 °C. Then, the supernatant and pellet fractions were separated by centrifugation at 1,500 ×g for 5 min, and the collected pellets were washed with 500 µL of the same buffer for three times. The mutant proteins attached to SRBCs were detected by western blotting using anti-His₆ antibody. Lane 1: STM6 (incubated for 30 min), Lane 2: STM6 (incubated over night), Lane 3: STM5 (incubated for 30 min).

4. Hemolytic activity of 14-meric and 7-meric forms of STM5




Figure S4. Time-course curves of the hemolysis of SRBCs by STM5 in 7-meric (red line) and 14-meric (blue line) forms (each 0.02 mg/mL) in PBS buffer (pH 7.4; containing 200 mM arginine hydrochloride) at 25 °C, as monitored by optical density at 700 nm.

5. Transmission electron microscopy of STM5 with 6.25 mM sodium deoxycholate





Figure S5. Transmission electron micrograph of STM5 in Tris-HCl buffer (pH 8.0; 50 mM; containing 200 mM NaCl, 200 mM arginine hydrochloride, and 6.25 mM sodium deoxycholate) negatively stained with uranyl acetate.

6. Electron paramagnetic resonance (EPR) spectroscopy of spin-labeled STM5

(A)



(B)




Figure S6. (A) EPR spectra of spin-labeled STM5 (a) in PBS buffer (pH 7.4; containing 200 mM arginine hydrochloride), (b) in suspension of SRBCs ($OD_{700} = 0.5$), and (c) in PBS buffer (pH 7.4; containing 6.25 mM sodium deoxycholate). Red line is the buffer solution containing spin-labeled STM5 in 7-meric form and blue line is in 14-meric form, respectively. (B) EPR spectra of spin-labeled STM5 in PBS buffer (pH 7.4; containing 200 mM arginine hydrochloride) containing (a) 7-meric form, (b) 14-meric form, and (c) spectrum (a) subtracted from (b). Black vertical lines were drawn for easy comparison of the peaks

7. Electron paramagnetic resonance (EPR) spectroscopy of spin-labeled STM2 in a monomeric form




Figure S7. EPR spectra of spin-labeled STM2 monomer in Tris-HCl buffer (pH 8.0; 50 mM; containing 200 mM NaCl).

8. Western blot analysis of STM5, STM5-PhM, STM5-PyM, and STM5-FIM





Figure S8. Western blot analysis of STM5 derivatives binding to SRBCs. Each protein (0.2 mg/mL) was incubated with SRBCs (50 mL, $OD_{700} = 0.5$) in PBS buffer (pH 7.4; containing 200 mM arginine hydrochloride) for a definite period of time at 25 °C. Then, the supernatant and pellet fractions were separated by centrifugation at $1,500 \times g$ for 5 min, and the collected pellets were washed with 500 μ L of the same buffer for three times. The mutant proteins attached to SRBCs were detected by western blotting using anti-His₆ antibody. Lane 1: STM5 without chemical modification (incubated for 30 min), Lane 2: STM5 without chemical modification (incubated for 180 min), Lane 3: STM5-FIM (incubated for 30 min), Lane 4: STM5-FIM (incubated for 180 min), Lane 5: STM5-PhM (incubated for 30 min), Lane 6: STM5-PyM (incubated for 30 min).

9. Hemolytic activity of PyM-modified stem-truncated Hla mutant K46C

(a)



(b)




Figure S9. (a) The crystal structure of wild-type Hla (left) and the schematic image of PyM-modified stem-truncated Hla mutant K46C (right). The red-colored residues indicate the site of K46 and the red spheres show the pyrenyl-maleimide moiety. (b) Time-course curves of the hemolysis of SRBCs by PyM-modified stem-truncated Hla mutant K46C (each 0.2 mg/mL) in PBS buffer (pH 7.4; containing 200 mM arginine hydrochloride) at 25 °C, as monitored by optional density at 700 nm.

10. The conductance of membranes containing STM5, STM5-PyM, and STM5-FIM





Figure S10. Current recording for the planar lipid bilayer containing (a) STM5-PyM, (b) STM5, and (c) STM5-FIM (each 0.13 mg/mL) at the applied voltage of +50 mV in HEPES buffer (pH 7.0, 10 mM, containing 100 mM KCl) at 20 °C. The insets show the enlarged views of the current recordings at the time periods denoted by arrows in (a).

11. Absorption and fluorescence spectroscopy of STM5-PyM

(a)



(b)




Figure S11. (a) UV-vis absorption spectra of STM5-PyM (2 mg/mL) in Tris-HCl buffer (pH 8.0; 50 mM; containing 200 mM NaCl and 200 mM arginine hydrochloride) without (blue line) and with (red line) 6.25 mM sodium deoxycholate at 25 °C. (b) Fluorescence spectra of STM5-PyM (2 mg/mL) in Tris-HCl buffer (pH 8.0; 50 mM; containing 200 mM NaCl and 200 mM arginine hydrochloride) without (blue line) and with (red line) 6.25 mM sodium deoxycholate at 25 °C.

12. Hemolytic activity of chemically-modified STM6




Figure S12. Time-course curves of the hemolysis of SRBCs by STM6 without chemical modification (green line), modified with *N*-(1-pyrenyl)maleimide (blue line) and modified with fluorescein-5-maleimide (red line) (each 0.02 mg/mL) in PBS buffer (pH 7.4; containing 200 mM arginine hydrochloride) at 25 °C, as monitored by optical density at 700 nm.

13. The far-UV CD spectra of STM5 and STM-PyM




Figure S13. The far-UV CD spectra of STM5 (green line) in phosphate buffer (pH 7.0; containing 150 mM NaCl) and STM-PyM (blue line) in phosphate buffer (pH 7.0; containing 150 mM NaCl and 5 mM dithiothreitol) (each 0.1 mg/mL) at 25 °C.